Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
132.60
-0.22 (-0.17%)
May 5, 2025, 4:00 PM EDT - Market closed
Abbott Laboratories Revenue
Abbott Laboratories had revenue of $10.36B in the quarter ending March 31, 2025, with 3.95% growth. This brings the company's revenue in the last twelve months to $42.34B, up 5.00% year-over-year. In the year 2024, Abbott Laboratories had annual revenue of $41.95B with 4.59% growth.
Revenue (ttm)
$42.34B
Revenue Growth
+5.00%
P/S Ratio
5.45
Revenue / Employee
$371,439
Employees
114,000
Market Cap
230.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.95B | 1.84B | 4.59% |
| Dec 31, 2023 | 40.11B | -3.54B | -8.12% |
| Dec 31, 2022 | 43.65B | 578.00M | 1.34% |
| Dec 31, 2021 | 43.08B | 8.47B | 24.47% |
| Dec 31, 2020 | 34.61B | 2.70B | 8.48% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Thermo Fisher Scientific | 42.90B |
ABT News
- 3 days ago - US judge allows testimony that Abbott and Mead Johnson preterm baby formula caused deadly disease - Reuters
- 4 days ago - MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races - PRNewsWire
- 5 days ago - Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom - CNBC
- 5 days ago - Best Dividend Aristocrats For May 2025 - Seeking Alpha
- 6 days ago - Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information - PRNewsWire
- 8 days ago - Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology - PRNewsWire
- 8 days ago - New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib - PRNewsWire
- 12 days ago - 2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market - Seeking Alpha